Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Yukako Tachibana-Kondo"'
Autor:
Toshiyuki Sakai, Yuko Aoki, Neal Rosen, Poulikos I. Poulikakos, Yoshihiro Sowa, Mikio Arisawa, Nobuo Shimma, Toshihiro Aoki, Hitoshi Iikura, Yukako Tachibana-Kondo, Yasushi Tomii, Yutaka Matsuda, Hiroshi Sakamoto, Takaaki Miura, Kazuhiro Ohara, Eric W. Joseph, Naoki Harada, Nobuya Ishii
Supplementary Table S3 - PDF file 54K, Binding constant between CH5126766 and non-phosphorylated MEK1. Non-phosphorylated His6-MEK1 (WT) was imobilized and affinities between His6-MEK1 and MEK inhibitors were analyzed with SPR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b5f67b52f9034817d856805e70d2d99
https://doi.org/10.1158/0008-5472.22395615
https://doi.org/10.1158/0008-5472.22395615
Autor:
Toshiyuki Sakai, Yuko Aoki, Neal Rosen, Poulikos I. Poulikakos, Yoshihiro Sowa, Mikio Arisawa, Nobuo Shimma, Toshihiro Aoki, Hitoshi Iikura, Yukako Tachibana-Kondo, Yasushi Tomii, Yutaka Matsuda, Hiroshi Sakamoto, Takaaki Miura, Kazuhiro Ohara, Eric W. Joseph, Naoki Harada, Nobuya Ishii
Tumors with mutant RAS are often dependent on extracellular signal–regulated kinase (ERK) signaling for growth; however, MEK inhibitors have only marginal antitumor activity in these tumors. MEK inhibitors relieve ERK-dependent feedback inhibition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d6d6624da24b766920d5ee7c74276a2
https://doi.org/10.1158/0008-5472.c.6504354.v1
https://doi.org/10.1158/0008-5472.c.6504354.v1
Autor:
Toshiyuki Sakai, Yuko Aoki, Neal Rosen, Poulikos I. Poulikakos, Yoshihiro Sowa, Mikio Arisawa, Nobuo Shimma, Toshihiro Aoki, Hitoshi Iikura, Yukako Tachibana-Kondo, Yasushi Tomii, Yutaka Matsuda, Hiroshi Sakamoto, Takaaki Miura, Kazuhiro Ohara, Eric W. Joseph, Naoki Harada, Nobuya Ishii
Supplementary Figure S1 - PDF file 70K, Induction of p27Kip1 protein and cell cycle arrest by CH5126766
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b272c3326137d6cf173146780cfce50
https://doi.org/10.1158/0008-5472.22395636.v1
https://doi.org/10.1158/0008-5472.22395636.v1
Autor:
Toshiyuki Sakai, Yuko Aoki, Neal Rosen, Poulikos I. Poulikakos, Yoshihiro Sowa, Mikio Arisawa, Nobuo Shimma, Toshihiro Aoki, Hitoshi Iikura, Yukako Tachibana-Kondo, Yasushi Tomii, Yutaka Matsuda, Hiroshi Sakamoto, Takaaki Miura, Kazuhiro Ohara, Eric W. Joseph, Naoki Harada, Nobuya Ishii
Supplementary Materials and Methods - PDF file 65K, Antibodies and kinase panel assays
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01d3675432925f1de4e4eff25dee105c
https://doi.org/10.1158/0008-5472.22395624
https://doi.org/10.1158/0008-5472.22395624
Autor:
Yasushi Tomii, Hiroshi Sakamoto, Toshihiro Aoki, Kazuhiro Ohara, Poulikos I. Poulikakos, Yoshihiro Sowa, Nobuo Shimma, Yuko Aoki, Neal Rosen, Mikio Arisawa, Yukako Tachibana-Kondo, Nobuya Ishii, Eric W. Joseph, Hitoshi Iikura, Naoki Harada, Toshiyuki Sakai, Takaaki Miura, Yutaka Matsuda
Publikováno v:
Cancer Research. 73:4050-4060
Tumors with mutant RAS are often dependent on extracellular signal–regulated kinase (ERK) signaling for growth; however, MEK inhibitors have only marginal antitumor activity in these tumors. MEK inhibitors relieve ERK-dependent feedback inhibition
Autor:
Takehito Isobe, Yasuko Sato, Kenji Morikami, Nobuya Ishii, Hitoshi Sase, Nukinori Akiyama, Yoshito Nakanishi, Yukako Tachibana-Kondo, Hirosato Ebiike, Hidetoshi Shindoh, Toshiyuki Mio, Kiyoaki Sakata, Toshihiko Fujii, Naoki Taka, Yuko Aoki, Toshiyuki Tsukaguchi
Publikováno v:
Cancer Research. 74:2729-2729
The fibroblast growth factor receptors (FGFR) are tyrosine kinases that are constitutively activated in a subset of tumors by genetic alterations such as gene amplification, point mutation, or chromosomal translocation/rearrangement. Recently, small-
Autor:
Yukako Tachibana-Kondo, Poulikos I. Poulikakos, Toshihiro Aoki, Hitoshi Iikura, Nobuo Shimma, Nobuya Ishii, Yuko Aoki, Yasushi Tomii, Neal Rosen, Hiroshi Sakamoto, Toshiyuki Sakai, Kazuhiro Ohara, Yoshihiro Sowa, Mikio Arisawa, Eric W. Joseph, Takaaki Miura, Yutaka Matsuda, Naoki Harada
Publikováno v:
Cancer Research. 71:3606-3606
Tumors with mutant BRAF or RAS are often dependent on the ERK signaling pathway. MEK and RAF inhibitors have significant antitumor activity in patients with BRAF mutant melanoma, but, thus far, MEK inhibitors have little activity in patients whose tu
Autor:
Nobuya Ishii1, Naoki Harada1, Joseph, Eric W.2, Kazuhiro Ohara1, Takaaki Miura1, Hiroshi Sakamoto1, Yutaka Matsuda1, Yasushi Tomii1, Yukako Tachibana-Kondo1, Hitoshi Iikura1, Toshihiro Aoki1, Nobuo Shimma1, Mikio Arisawa1, Yoshihiro Sowa3, Poulikakos, Poulikos I.2, Rosen, Neal2 rosenn@mskcc.org, Yuko Aoki1, Toshiyuki Sakai3
Publikováno v:
Cancer Research. Jul2013, Vol. 73 Issue 13, p4050-4060. 11p.